Home/Pipeline/Influenza Antibodies

Influenza Antibodies

Influenza

Research/Pre-clinicalActive

Key Facts

Indication

Influenza

Phase

Research/Pre-clinical

Status

Active

Company

new/era/mabs

About new/era/mabs

new/era/mabs is a private, platform-based biotech service provider leveraging its proprietary selmax technology for high-throughput antibody discovery. Its core value proposition is delivering antibody leads four times faster than conventional methods by using immortal antigen-specific cell pools that allow for infinite screening. The company serves research, diagnostic, and therapeutic partners with tailored antibody sets and manufacturing, with notable applications in infectious diseases (e.g., SARS-CoV-2) and neurodegenerative targets. It appears to be in an early-revenue stage, collaborating with academic and industry partners to advance its platform.

View full company profile

Therapeutic Areas

Oncology Immunology Infectious Diseases Neurodegenerative Diseases

Other Influenza Drugs

Drug	Company	Phase	Status
PanCytoVir™ (oral probenecid)	TrippBio	IND Submitted	Active
Mimotopes-004	Mimotopes	Preclinical	Active
Next-Gen / Universal Flu Vaccines	CSL Seqirus	Research / Early Clinical	Active
Oseltamivir 75 mg	MSN Laboratories	Commercial	Active
AI Programme - Influenza	Poolbeg Pharma	Discovery	Active - Target/Candidate ID
Influenza Countermeasure Program	DynPort Vaccines	Not Specified	Active
Influenza Vaccine	Medigen	Preclinical	Active
Nasal Influenza Vaccine	Abera Bioscience	Pre-clinical	Active
Zapnometinib (ATR-002)	Atriva Therapeutics	Phase 2	Active
EV25	Eradivir	Pre-clinical	Active
Not Specified	New Amsterdam Sciences	Pre-clinical	Active
Influenza Program	Arisan Therapeutics	Preclinical	Active